fashion -WSS

fashion

author：focus 2025-09-27 13:11:09 - browse：2

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Pharma companies must ensure equitable access to obesity drugs

WSS

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Drastic changes should bring profitability, startup health insurers say

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

The system is set up to fail children with medical complexity

A biotech analyst on neuroscience, placebo effect, not over

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

In Memoriam: Notable people who died in 2023

Health care court cases: Humana, Sutter, Novant

DIEP, the 'gold standard' of breast reconstruction, is under threat

Naloxone nonprofit donates 200,000 doses after FDA approval

Apple is now the first public company to be valued at $3 trillion

Curing rare childhood diseases will falter unless Congress steps up

Sports medicine is finally prioritizing gender equality

Wegovy’s successful heart trial raises vital question about weight loss

Apple is now the first public company to be valued at $3 trillion

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

knowledge

Anavex keeps shifting the goalposts in its clinical trials

Drastic changes should bring profitability, startup health insurers say

Report captures long Covid’s disabling effects and policy challenges

The best solution to the drug shortages problem

Coercive sterilizations revealed by STAT prompt outrage

ALS patient reclaims some autonomy thanks to wearable 'robot'

Wikipedia

leisure time

hotspot

hotspot